CMS details program to use outcomes-based agreements to pay for sickle cell gene therapies
US Medicaid programs will test a payment model that will reimburse multimillion-dollar gene therapies based on patient outcomes, in an early step toward efforts to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
